Diet Pill Reshapes Spending
New Oral Weight Loss Pill GLP-1 Reshapes UK Spending Habits, Study Finds
Anonymous
A new study says the UK's first oral weight loss pill could reshape how millions of British people spend their money. PwC Strategy& found that GLP-1 users — people taking drugs like Wegovy — could grow from 3 million to 7.4 million by 2027, reaching roughly 15% of all UK adults.
The trigger is the UK medicines regulator's approval of an oral tablet version of Wegovy — removing the need for injections. Tim Robertson, a partner at PwC Strategy&, called it "a game-changer" that removes "needle-phobia" and cold-storage barriers. The result, the study warns, will be a measurable shift in where billions of pounds are spent each year.
Snack and Drink Sales Face a £4 Billion Hit
The numbers behind the spending shift are striking. According to PwC Strategy&, 70% of GLP-1 users already spend less on snacks, confectionery, and crisps. Half cut back on sugary drinks. And 44% spend less on alcohol. The study estimates that up to £4 billion in annual grocery spending could move away from these "appetite-led" categories by 2027.
Grocery analysts at Barclays have flagged a structural threat to supermarkets. If 15% of the population stops impulse-buying at the checkout, the high-margin confectionery aisle faces serious long-term pressure. Stores like Tesco and Sainsbury's may need to redesign their layouts entirely.
Wellness, Fresh Food, and Fitness Are the Big Winners
The money doesn't disappear — it moves. PwC Strategy& found that 60% of GLP-1 users spend more on fresh fruit and vegetables. Over half increase spending on vitamins and supplements. And 20% spend more on gym memberships and fitness clothing. Companies like Nestlé and Danone are already developing high-protein products aimed directly at GLP-1 users, The Wall Street Journal reported.
There is also an unexpected cosmetic boom. As millions lose weight quickly, demand for skin-tightening treatments and aesthetic procedures is expected to rise sharply, shifting spending toward the cosmetic surgery and skincare sectors, according to Dermatology Times.
NHS Faces Both a Cost Burden and Long-Term Savings
Wegovy costs the NHS between £72 and £175 per patient each month. Scaling that across millions of users is expensive. But NICE estimates that if the 7.4 million user target is reached, long-term savings from fewer diabetes, stroke, and heart disease cases could run into billions of pounds.
Still, doctors urge caution. Dr. Simon Cork of Anglia Ruskin University told the Science Media Centre that "the infrastructure for monitoring millions of people on these drugs — such as checking for muscle loss or gastrointestinal side effects — simply doesn't exist yet in the NHS." The pill makes access easier, but the health system may not be ready for the scale.
Critics Warn Pill Could Widen the Health Inequality Gap
Not everyone is celebrating. Groups like Action on Sugar, writing in The British Medical Journal, argue the pill is a "sticking plaster" that lets the government avoid regulating ultra-processed food. Their concern: instead of fixing a broken food environment, the UK is medicating its way through it.
There is also an equity problem. The pill costs around £150–£200 per month privately. Those who can afford it will see fast health gains. Those waiting on a stretched NHS could wait years. The King's Fund warns this risks widening the health gap between rich and poor — turning a public health breakthrough into a privilege for the few.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
7
Articles
7
Reach
7
A
AnonymousAuthor
